Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
NCT00303719Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2002
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of fludarabine, cyclophosphamide, antithymocyte globulin rabbit, cyclosporine and mycophenolate mofetil in leukemia, lymphoma, multiple myeloma (MM) and 3 more (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Neutrophil and Donor Cell Engraftment at Day 100. Started Mar 2002; status: terminated.
02
Drugs
fludarabinecyclophosphamideantithymocyte globulin rabbitcyclosporinemycophenolate mofetil
03
Conditions
leukemialymphomamultiple myeloma (MM)myelodysplastic syndrome (MDS)kidney cancer
Beyond the preview
Go deeper on NCT00303719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00303719.